Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home News & Views

News & Views

News & Views

Telix Pharmaceuticals and RefleXion Medical Enter Strategic Collaboration for Treatment of High-Risk Cancers

ASX, News,

Telix Pharmaceuticals Limited announces it has entered into a strategic collaboration agreement with RefleXion…

Read more

Telix Receives FDA Feedback on Phase 3 Trial Design for Prostate Cancer Therapy Product

Clinical, News,

Telix Pharmaceuticals Limited announces that the FDA has provided feedback that will enable the Company to finalize the Phase 3 PROSTACT…

Read more

Telix Granted FDA Breakthrough Therapy Designation for Renal Cancer Imaging Product

ASX, News,

Telix announces that the FDA has granted Breakthrough Therapy (BT) designation for Telix’s renal cancer imaging product…

Read more

Recommencement of ZIRCON Phase III Trial Recruitment in EU

Clinical, News,

Telix Pharmaceuticals Limited announces that the Company’s ZIRCON phase III trial of TLX250-CDx has recommenced patient recruitment in…

Read more

Presentation to Jefferies Virtual Healthcare Conference

Events, News,

Telix Pharmaceuticals Limited has today announced that Group CBO Dr. David Cade presented at Jefferies Virtual Healthcare…

Read more

Telix Pharmaceuticals Appoints Dr Colin Hayward as Chief Medical Officer

News,

Telix Pharmaceuticals announces that Dr Colin Hayward has joined Telix’s executive leadership team in the role of Chief Medical Officer…

Read more

Telix presents IPAX-1 study in glioblastoma treatment at ASCO 2020

Events, News,

Telix Pharmaceuticals is pleased to announce that the IPAX-1 study will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program to be held May 29…

Read more

Telix Pharmaceuticals and Pharmalogic Enter US Distribution Agreement for Prostate Cancer Imaging

ASX, News,

Telix Pharma (U.S.) announces it has entered into a commercial distribution agreement with Pharmalogic Holdings…

Read more

Telix Pharmaceuticals Granted July Pre-IND Meeting with US FDA for Phase III ProstACT Study

ASX, News,

Telix has been granted a Type B pre-IND meeting with the FDA in relation to the Company’s planned Phase III ProstACT trial for…

Read more

Telix AGM – Chairman and CEO Addresses

ASX, News,

Telix is pleased to provide the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of…

Read more
1 … 35 36 37 38 39 … 43

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings